Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 4Head & Neck 4Gynecologic 4Genitourinary 3Dermatologic 3Lymphoid 2Breast 2Other solid neoplasm 1NET 1Endocrine 1

Conditions

Hodgkin Disease 36Lymphoma 34Lymphoma, Non-Hodgkin 24Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 18Lymphoma, B-Cell 16Recurrence 15Melanoma 14Neoplasms 12Mycosis Fungoides 9Lymphoma, T-Cell 9Breast Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, T-Cell, Cutaneous 7Lymphoma, B-Cell, Marginal Zone 7Head and Neck Neoplasms 7Sezary Syndrome 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lung Neoplasms 6Carcinoma, Renal Cell 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasm Metastasis 5Lymphoma, T-Cell, Peripheral 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4

Interventions

pembrolizumab 2fludarabine 1epacadostat 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Carboxylesterase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × pembrolizumab × Lymphoid × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡